LANXESS AG UNSP.ADR 1/5 (LX9B) - Total Liabilities
Based on the latest financial reports, LANXESS AG UNSP.ADR 1/5 (LX9B) has total liabilities worth €4.28 Billion EUR (≈ $5.00 Billion USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check LANXESS AG UNSP.ADR 1/5 (LX9B) asset resilience to evaluate the company's liquid asset resilience ratio.
LANXESS AG UNSP.ADR 1/5 - Total Liabilities Trend (2021–2024)
This chart illustrates how LANXESS AG UNSP.ADR 1/5's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see LANXESS AG UNSP.ADR 1/5 balance sheet assets.
LANXESS AG UNSP.ADR 1/5 Competitors by Total Liabilities
The table below lists competitors of LANXESS AG UNSP.ADR 1/5 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tecan Group AG
SW:TECN
|
Switzerland | CHF656.74 Million |
|
SoftwareONE Holding AG
SW:SWON
|
Switzerland | CHF5.81 Billion |
|
BBMG Corp Class A
SHG:601992
|
China | CN¥174.70 Billion |
|
Guangdong Advertising Co Ltd
SHE:002400
|
China | CN¥7.50 Billion |
|
Syngene International Limited
NSE:SYNGENE
|
India | Rs18.07 Billion |
|
Alembic Pharmaceuticals Limited
NSE:APLLTD
|
India | Rs30.81 Billion |
|
Yifan Xinfu Pharmaceutical Co Ltd
SHE:002019
|
China | CN¥4.08 Billion |
|
Photronics Inc
NASDAQ:PLAB
|
USA | $237.37 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down LANXESS AG UNSP.ADR 1/5's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See LANXESS AG UNSP.ADR 1/5 balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.60 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.52 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how LANXESS AG UNSP.ADR 1/5's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for LANXESS AG UNSP.ADR 1/5 (2021–2024)
The table below shows the annual total liabilities of LANXESS AG UNSP.ADR 1/5 from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €5.12 Billion ≈ $5.98 Billion |
-0.76% |
| 2023-12-31 | €5.16 Billion ≈ $6.03 Billion |
-24.81% |
| 2022-12-31 | €6.86 Billion ≈ $8.02 Billion |
+1.39% |
| 2021-12-31 | €6.77 Billion ≈ $7.91 Billion |
-- |
About LANXESS AG UNSP.ADR 1/5
LANXESS Aktiengesellschaft, a specialty chemicals company, engages in the development, manufacture, and marketing of chemical intermediates, additives, and consumer protection products worldwide. It operates through three segments: Consumer Protection, Specialty Additives, and Advanced Intermediates. The company provides material protection products; disinfectant, hygiene, and preservative soluti… Read more